E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Recurrent or refractory malignant solid tumors in children between 2 and 17 year of age |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10065147 |
E.1.2 | Term | Malignant solid tumor |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To determine the dose of R1507, a monoclonal antibody to the Type I Insulin-like Growth Factor Receptor (IGF-IR), that achieve serum drug exposure levels (AUC) in children and adolescents with advanced solid tumors that are equivalent to the exposures in adults at the adult recommended doses of 9mg/kg administered on a weekly schedule and 16 mg/kg administered every 3 weeks.
- To determine the maximum tolerated dose (MTD) of R1507 in children and adolescents with advanced solid tumors IF dose-limiting toxicity is observed in 2 or more patients at any dose level on the weekly or every 3 week schedules. |
|
E.2.2 | Secondary objectives of the trial |
- Describe the tolerability and adverse event profile of R1507 administered weekly or every 3 weeks in children and adolescents with advanced solid tumors.
- Describe the pharmacokinetic profile of R1507 after single and repeated dosing in children and adolescents with advanced solid tumors.
- Describe any anti-tumor responses to R1507.
- Describe the early effects of R1507 on tumors by PET scan.
- Investigate the expression of IGF-related signaling pathways in archival tumor tissue using immunohistochemistry.
- Assess the development of an immunologic response (HAHA) to R1507.
- Assess changes in IGF-1R related signaling molecules in patient serum samples.
- Determine the appropriate dose of R1507 for further disease-directed/ phase II studies in children and adolescents with advanced solid tumors. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Pediatric patients aged 2-17 years of age;
- Histologically confirmed solid tumors;
- Cancer which has relapsed after, or failed to respond to, curative therapy, or no other potentially curative treatment options available. |
|
E.4 | Principal exclusion criteria |
- Treatment with corticosteroids within past 2 weeks;
- Current or past use of anti-IGF-1R antibodies;
- Current treatment with immunosuppressive agents;
- Patients with diabetes mellitus;
- Known HIV or hepatitis B or C;
- Hypersensitivity to any of the components of R1507 or to monoclonal antibodies. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Serum drug exposure level equivalent to exposure in adults at adult recommended doses
2. Maximum tolerated dose (adverse events, laboratory parameters) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline, Weeks 1, 2, 3, 4, 5, and 6, then every 3 weeks thereafter (Weeks 9, 12, etc.) and at final visit. |
|
E.5.2 | Secondary end point(s) |
1. Tumor response rate according to RECIST criteria
2. Percentage of participants with adverse events and serious adverse events
3. Percentage of participants with laboratory abnormalities
4. Percentage of participants with formation of human anti-human antibodies (HAHAs)
5. Immune reconstitution (Quantitative evaluation of lymphocyte subsets in the peripheral blood)
6. Maximum plasma concentration (Cmax)
7. Time to reach the maximum concentration (Tmax)
8. Minimum concentration per dosing interval (Cmin)
9. Area under the concentration-time cure (AUC)
10. Clearance (CL)
11. Volume of distribution at steady state (VDss)
12. Terminal elimination half-life (T1/2)
13. Maximum Standardized Uptake Value (SUV) in tumor pretreatment versus one day after the second dose.
14. Average SUV in tumor pretreatment versus one day after the second dose
15. Expression of IGF-related signaling pathways in archival tumor tissue |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Measurements completed at Screening, Week 1, Week 2, Week 3, Subsequent Weeks, Final Visit (7 days post-dose) and Follow-up Visit (30 days post-dose)
PK Sampling Schedule:
qW Dosing: Week 1 (Days 1, 2, 3 and 4 pre-dose, end of infusion and 6, 24, 48 and 72 hours after dosing), Week 2, 4 and 6 (Day 1 pre-dose and end of infusion), Week 8 and 10 (Day 1 pre-dose), and Weeks 1 and 4 off-study (Days 7 and 30).
q3W Dosing: Cycle 1 Day 1 (pre-dose, end of infusion and 6, 24, 48 and 72 hours after dosing); Cycle 1 Days 8 and 15; Cycle 2 Day 1 (pre-dose and end of infusion); Cycle 3 Day 1 (pre-dose and end of infusion); Cycle 3 Day 8 Cycle 4 Day 1 (pre-dose and end of infusion); Final and Follow-up Visit (7 and 30 days after last dose) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Dose-finding in children and adolescents |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |